Literature DB >> 28468587

MicroRNA-34 dysregulation in gastric cancer and gastric cancer stem cell.

Narjes Jafari1, Saeid Abediankenari1.   

Abstract

Gastric cancer is a major cause of cancer mortality worldwide, with a low survival rate for patients with advanced forms of the disease. Over the recent decades, the investigation of the pathophysiological mechanisms of tumourigenesis has opened promising avenues to understand some of the complexities of cancer treatment. However, tumour regeneration and metastasis impose great difficulty for gastric cancer cure. In recent years, cancer stem cells - a small subset of tumour cells in many cancers - have become a major focus of cancer research. Cancer stem cells are capable of self-renewal and are known to be responsible for tumour initiation, metastasis, therapy resistance and cancer recurrence. Recent studies have revealed the key role of microRNAs - small noncoding RNAs regulating gene expression - in these processes. MicroRNAs play crucial roles in the regulation of a wide range of biological processes in a post-transcriptional manner, though their expression is dysregulated in most malignancies, including gastric cancer. In this article, we review the consequences of aberrant expression of microRNA-34 in cancer and cancer stem cells, with a specific focus on the miR-34 dysregulation in gastric cancer and gastric cancer stem cells. We address the critical effects of the aberrant expression of miR-34 and its target genes in maintaining cancer stem cell properties. Information collection and discussion about the advancements in gastric cancer stem cells and microRNAs can be useful for providing novel insights into patient treatment.

Entities:  

Keywords:  Gastric cancer; dysregulation; gastric cancer stem cell; microRNA-34

Mesh:

Substances:

Year:  2017        PMID: 28468587     DOI: 10.1177/1010428317701652

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  12 in total

1.  MicroRNA-214 promotes the proliferation, migration and invasion of gastric cancer MKN28 cells by suppressing the expression of Dact2.

Authors:  Lei Zhao; Weiwei Fan; Yujing Fan; Shanling Gao
Journal:  Exp Ther Med       Date:  2018-09-19       Impact factor: 2.447

2.  Clinical role of miR-421 as a novel biomarker in diagnosis of gastric cancer patients: A meta-analysis.

Authors:  Yingying Xu; Guiping Wang; Wenqing Hu; Songbing He; Dandan Li; Ping Chen; Jinjie Zhang; Yongshun Gao; Duonan Yu; Liang Zong
Journal:  Medicine (Baltimore)       Date:  2022-05-13       Impact factor: 1.817

Review 3.  Adipocyte, Immune Cells, and miRNA Crosstalk: A Novel Regulator of Metabolic Dysfunction and Obesity.

Authors:  Sonia Kiran; Vijay Kumar; Santosh Kumar; Robert L Price; Udai P Singh
Journal:  Cells       Date:  2021-04-24       Impact factor: 6.600

4.  MicroRNA‑137 exerts protective effects on hypoxia‑induced cell injury by inhibiting autophagy/mitophagy and maintaining mitochondrial function in breast cancer stem‑like cells.

Authors:  Qiongying Hu; Yun Yuan; Yeke Wu; Yongliang Huang; Ziyi Zhao; Chong Xiao
Journal:  Oncol Rep       Date:  2020-08-03       Impact factor: 3.906

5.  Dual role for miR-34a in the control of early progenitor proliferation and commitment in the mammary gland and in breast cancer.

Authors:  Paola Bonetti; Montserrat Climent; Fabiana Panebianco; Chiara Tordonato; Angela Santoro; Matteo Jacopo Marzi; Pier Giuseppe Pelicci; Andrea Ventura; Francesco Nicassio
Journal:  Oncogene       Date:  2018-08-09       Impact factor: 9.867

Review 6.  Current Understanding of Circular RNAs in Gastric Cancer.

Authors:  Xiaohuan Tang; Jiaming Zhu; Yuanda Liu; Chao Chen; Tianzhou Liu; Jingjing Liu
Journal:  Cancer Manag Res       Date:  2019-12-13       Impact factor: 3.989

7.  miR-34a mimic or pre-mir-34a, which is the better option for cancer therapy? KatoIII as a model to study miRNA action in human gastric cancer cells.

Authors:  Narjes Jafari; Saeid Abediankenari; Hadi Hossein-Nataj
Journal:  Cancer Cell Int       Date:  2021-03-19       Impact factor: 5.722

8.  MicroRNA-564 inhibits the progression of non-small cell lung cancer via targeting plexin A4.

Authors:  Hui Ding; Liangpeng Li; Biao Gu; Yaojun Ni; Sheng Chen
Journal:  Exp Ther Med       Date:  2021-02-13       Impact factor: 2.447

9.  miR-654-5p promotes gastric cancer progression via the GPRIN1/NF-κB pathway.

Authors:  Weidong Zhou; Peifei Li; Peihua Jin
Journal:  Open Med (Wars)       Date:  2021-11-09

10.  The miR-567/RPL15/TGF-β/Smad axis inhibits the stem-like properties and chemo-resistance of gastric cancer cells.

Authors:  Yuan Ma; Hua Xue; Weifeng Wang; Yaying Yuan; Fang Liang
Journal:  Transl Cancer Res       Date:  2020-05       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.